Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
J Dermatolog Treat. 2024 Dec;35(1):2334791. doi: 10.1080/09546634.2024.2334791. Epub 2024 Apr 2.
Generalized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pregnant women has not been reported to date. Here, we report a pregnant woman with refractory GPP who did not respond well to systemic steroids. Administration of spesolimab resulted in complete control of the disease and the birth of a healthy baby. Our case demonstrates that IL-36RN inhibitors are a potentially effective and safe treatment option for GPP in pregnancy.
妊娠泛发性脓疱型银屑病（GPP）可导致母婴严重并发症。该病的治疗具有挑战性，尤其是在难治性和重度病例中。迄今为止，针对妊娠 GPP 尚无基于证据的治疗指南。Spesolimab 是一种针对 IL-36 受体的人源单克隆抗体，最近作为 GPP 发作的新疗法引起了关注。这种生物制剂可迅速且持续地控制 GPP 发作的症状，但迄今为止尚未有报道其在孕妇中的应用。在此，我们报告了一例患有难治性 GPP 的孕妇，她对全身皮质类固醇反应不佳。Spesolimab 的给药导致疾病完全得到控制，并产下了健康的婴儿。我们的病例表明，IL-36RN 抑制剂是治疗妊娠 GPP 的一种潜在有效且安全的治疗选择。
